சலீம் சையத் மீஜுஹோ News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from சலீம் சையத் மீஜுஹோ. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In சலீம் சையத் மீஜுஹோ Today - Breaking & Trending Today

Cytokinetics Inc (CYTK) Q1 2021 Earnings Call Transcript


Operator
Good afternoon, and welcome, ladies and gentlemen, to Cytokinetics First Quarter 2021 Conference Call. At this time, I would like to inform you that this call is being recorded and that all participants are in a listen-only mode. At the company s request, we will open the call for questions-and-answers after the presentation.
I will now like to turn the call over to Diane Weiser, Cytokinetics Senior Vice President of Corporate Communications and Investor Relations. Please go ahead.
Diane Weiser
Senior Vice President of Corporate Communications & Investor Relations
Good afternoon, and thanks for joining us on the call today. Robert Blum, our President and Chief Executive Officer, will kick off the call with an overview of the quarter and recent developments. Then Fady Malik, our EVP of Research and Development, will provide an update on omecamtiv mecarbil, including progress following a recent meeting with FDA and what to expect from upcoming analys ....

United States , Ji Xing , Morgan Stanley , Salim Syed Mizuho , Stuart Kupfer , Robert Wong , Charles Duncan , Charles Duncan Cantor Fitzgerald , Ted Tentoff , Fady Malik , Andrew Callos , Ted Tentoff Piper Sandler , John Teerlink , Salim Syed , Piper Sandler , Diane Weiser , Robert Blum , Emanuela Branchetti , American Chemical Society Spring , Cytokinetics Inc , Wyeth Pharmaceuticals , American College Of Cardiology , Ji Xing Pharmaceuticals , Corporate Communications Investor Relations , American Chemical Society Annual Meeting , Cantor Fitzgerald ,

Cytokinetics Inc (CYTK) Q4 2020 Earnings Call Transcript


Cytokinetics Inc (CYTK) Q4 2020 Earnings Call Transcript
Motley Fool Transcribers
© The Motley Fool
Logo of jester cap with thought bubble.
Cytokinetics Inc (NASDAQ: CYTK)
Operator
Good afternoon, and welcome, ladies and gentlemen, to Cytokinetics Fourth Quarter 2020 Conference Call. [Operator Instructions]
I will now turn the call over to Diane Weiser, Cytokinetics Senior Vice President of Corporate Creations and Investor Relations. Please go ahead.
This article is a transcript of this conference call produced for The Motley Fool. While we strive for our Foolish Best, there may be errors, omissions, or inaccuracies in this transcript. As with all our articles, The Motley Fool does not assume any responsibility for your use of this content, and we strongly encourage you to do your own research, including listening to the call yourself and reading the company s SEC filings. Please see our ....

Ji Xing , United States , Morgan Stanley , Raymond James , Salim Syed Mizuho , Stuart Kupfer , Charles Duncan , Robert Wong , Charles Duncan Cantor Fitzgerald , Muna Bhanji , Carter Gould , Nancy Wysenski , Greg Suvannavejh , Carter Gould Barclays , Mike Felker , Ted Tentoff , Robertc Wong , Jason Butler , Fady Malik , Fadyi Malik , Ted Tentoff Piper Sandler , John Teerlink , Salim Syed , Piper Sandler , Diane Weiser , Roberti Blum ,

Coherus BioSciences Inc (CHRS) Q4 2020 Earnings Call Transcript


Operator
Ladies and gentlemen, thank you for standing by, and welcome to the Fourth Quarter and Full Year 2020 Coherus BioSciences Conference Call. [Operator Instructions]
I would now like to turn the conference over to your host today, Mr. McDavid Stilwell. Sir, please go ahead.
McDavid Stilwell
Executive Vice President, Corporate Development, Investor Relations, and Financial Strategy
Thank you. Good afternoon, everyone, and thank you for joining us. We issued a press release earlier announcing our 2020 fiscal year and fourth quarter results and the release can be found on the Coherus BioSciences website. Today s call includes forward-looking statements regarding Coherus current expectations. These statements include, but are not limited to, our ability to advance our biosimilar and immuno-oncology product candidates through development and registration. ....

United States , Gregory Gilbert Truist , Dennism Lanfear , Salim Syed Mizuho , Jean Viret , Georgi Yordanov , Jason Gerberry , Balaji Prasad Barclays , Neulasta Onpro , Vincentr Anicetti , Vince Anicetti , Balaji Prasad , Mcdavid Stilwell , Denny Lanfear , Chris Schott Jpmorgan , Georgi Yordanov Cowen , Salim Syed , Gregg Gilbert , Chris Thompson , Chris Schott , Coherus Biosciences , Junshi Biosciences , Jean Frederic Viret , Mohit Bansal Citi , Mohit Bansal , Coherus Biosciences Inc ,